Coverage and Compliance of Human Papillomavirus Vaccines in Paris: Demonstration of Low Compliance With Non-School-Based Approaches

References 

1. Harper DM. Prevention of human papillomavirus infections and associated diseases by vaccination: A new hope for global public health. Public Health Genomics. 2009;12:319–330
   • CrossRef
2. Koulova A, Tsui J, Irwin K, et al. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine. 2008;26:6529–6541
   • CrossRef
3. Lévy-Bruhl D, Bousquet V, King LA, et al. country specific VENICE gate keepers and contact points The current state of introduction of HPV vaccination into national immunisation schedules in Europe: Results of the VENICE 2008 survey. Eur J Cancer. 2009;45:2709–2713
   • Abstract
   • Full Text
   • Full-Text PDF (1721 KB)
   • CrossRef
4. Bergeron C, Largeron N, McAllister R, et al. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care. 2008;24:10–19
5. Vaccination schedule and recommendations from the “Haut conseil de la santé publique” in France. Bull Epidémiol Hebdomadaire. 2009;16-17:145–176
6. Breakthrough Vaccine Victim of Bad Publicity. Canadian National Post, February 19, 2008. Available at: www.nationalpost.com/news/canada/Story.html?id=317535.
7. Brabin L, Roberts SA, Stretch R, et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: Prospective cohort study. BMJ. 2008;336:1056–1058
   • CrossRef
8. Brotherton JM, Deeks SL, Campbell-Lloyd S, et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell. 2008;32:457–461
9. Centers for Disease Control and Prevention (CDC). Vaccination coverage among adolescents aged 13-17 years—United States, 2007. Morb Mortal Wkly Rep. 2008;57:1100–1103
10. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927
    • CrossRef
11. Paavonen J, Naud P, Salmerón J, et al. HPV PATRICIA Study Group Greenacre M. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomized study in young women. Lancet. 2009;374:301–314
    • Abstract
    • Full Text
    • Full-Text PDF (302 KB)
    • CrossRef
12. Stephan M, Melinand C, Darras A, et al. Compliance with HPV Vaccination in Girls and Young Women in France: First Results. Paris, France: Eurogin; 2008;P VC-3. Available at http://www.eurogin.com/2008/EUROGIN2008_LastMinuteAbstracts.pdf
13. Stephan M, Melinand C, Darras A. Compliance with HPV Vaccination in Girls and Young Women in Germany: First Results. Paris, France: Eurogin; 2008;P VC-2. Available at http://www.eurogin.com/2008/EUROGIN2008_LastMinuteAbstracts.pdf
14. Watson M, Shaw D, Molchanoff L, et al. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust N Z J Public Health. 2009;33:365–370
    • CrossRef
15. Deutsch P, Joannard N. Programme Régional d'Ile de France—Maladies à Prévention Vaccinale. Paris, France: Colloque Vaccination en Ile-de-France, 28 avril; 2009;
16. Kim JJ, Brisson M, Edmunds WJ, et al. Modeling cervical cancer prevention in developed countries. Vaccine 26 (Suppl 10):K76–86.
17. Schiller JT, Castellsagué X, Villa LL, et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008;26(Suppl 10):K53–K61
    • CrossRef